|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Myeloid cell leukemia 1 (Mcl-1) overexpression is found in various human tumors and has emerged as a promising new target for pancreatic cancer treatment.
|
30890228 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although expression levels of BCL-X<sub>L</sub> and MCL-1 did not correlate with patient outcome, a combination of BH3 mimetics to target these proteins resulted in decreased clonogenic potential and enhanced apoptosis in all preclinical models, including tumor tissue resected from patients, as well as a reduction of tumor volume in a zebrafish xenograft model of SCCHN.
|
31801952 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, combined use of the selective Mcl-1 inhibitor VU661013 with ABT-263 resulted in tumor cell apoptosis and diminished tumor growth <i>in vivo</i>.
|
31595181 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Compound 42 binds to Mcl-1 with picomolar affinity and inhibited growth of Mcl-1-dependent tumor cell lines in the nanomolar range.
|
30929420 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies have emphasized a key role for the anti-apoptotic Bcl-2 family member Mcl-1 in conferring tumor cell survival and drug resistance in breast cancer (BC).
|
30374681 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCL-1, a potential mediator of resistance to ABT-263, was expressed in all cell lines and HNSCC patient tumors, in addition to BCL-xL.
|
30728900 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Addition of the CDK4/6 inhibitor LEE011 to BYL719 caused a simultaneous reduction of p-RB and p-S6, and a more complete inhibition of p-S6, leading to decreased expression of the pro-survival protein MCL-1, an induction of apoptosis, and an enhanced reduction of tumor growth in a PDX model of TNBC.
|
31101835 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Iterative mouse modeling and comparative oncogenomics analysis show that MYC-overexpression strongly reshapes the CNA landscape of BRCA1-deficient mammary tumors and identify MCL1 as a collaborating driver in these tumors.
|
30674894 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Four somatic alterations, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), Fos proto-oncogene, AP-1 transcription factor subunit (FOS), MCL1 apoptosis regulator (MCL1), and phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) were detected in the tumor tissue using a Next generation sequencing (NGS) technology.
|
31305404 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of the antiapoptotic protein Mcl-1 provides a survival advantage to some cancer cells, making inhibition of this protein an attractive therapeutic target for the treatment of certain types of tumors.
|
31736296 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, we show that pharmacologic inhibition of mTORC1 lowers MCL-1 levels and further sensitizes cells to navitoclax <i>in vitro</i> and leads to tumor regressions <i>in vivo</i>.
|
30224339 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High patients' tumor MCL-1 expression was correlated with shorter overall and recurrence-free survival.
|
31384313 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RAE induced a decrease in Mcl-1 in cultured CCA cells and in xenograft CCA tumors.
|
30633583 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CycT also decreases the levels of two regulators promoting OXPHOS, MYC and MCL1, and effectively alleviates tumor hypoxia.
|
30723259 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RNA-seq analysis revealed that ARQ531 constrained tumor cell proliferation and survival through Bruton's tyrosine kinase and transcriptional program dysregulation, with proteasome-mediated MYB degradation and depletion of short-lived proteins that are crucial for tumor growth and survival, including ERK, MYC and MCL1.
|
31624110 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that N6-isopentenyladenosine affects colorectal cancer proliferation in in vitro models carrying different mutational status of <i>FBXW7</i> and <i>TP53</i> genes, and in HCT116 xenografts in SCID mice, by increasing the expression of the well-established tumor suppressor FBXW7, a component of the SCF-E3 ubiquitin ligase complex that promotes degradation of various oncoproteins and transcription factors, such as c-Myc, SREBP and Mcl1.
|
31569395 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among all Bcl-2 antiapoptotic members, Mcl-1 expression (but not Bcl-2 or Bcl-xL) was found to be upregulated in both chemoresistant OSCC lines and chemoresistant tumors when compared with their respective sensitive counterparts.
|
30395230 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Members of the BCL-2 family of proteins regulate the process of apoptosis by its promotion or inhibition and overexpression of the pro-survival anti-apoptotic proteins (Bcl-2, Bcl-xL, and Mcl-1) has been associated with tumor maintenance, growth and progression Small molecules and peptides which bind the BH3 binding groove of these proteins have been explored in the recent times for their anticancer potential.
|
30526410 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The overexpression of anti-apoptotic proteins (i.e., Bcl-2, Bcl-X<sub>L</sub> or Mcl-1) is a hallmark of cancer and favors tumor cell survival and resistance to therapy.
|
30076373 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A reduction in signal transducer and activator of transcription (STAT) 3 phosphorylation and its effectors (BCL-2, MCL-1) in tumors during follow-up was significantly associated with clinical response.
|
28843487 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LY2874455 treatment of PDX-bearing mice was associated with tumour cell loss of MCL1 and cell necrosis.
|
29408314 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, SLN-curc reduced the expression of proteins involved in cell proliferation and apoptosis (XIAP and Mcl-1) in HL tumor extracts.
|
29679536 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using a novel class of potent and selective MCL1 inhibitors, we demonstrate that concurrent MEK + MCL1 inhibition induces apoptosis and tumor regression in <i>KRAS</i>-mutant non-small cell lung cancer (NSCLC) models, which respond poorly to MEK inhibition alone.
|
30254092 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Quercetin and green tea reduced tumor growth in HL-60 xenografts accompanied by decreased expression of anti-apoptotic proteins, BCL-2, BCL-XL and MCL-1 and increased expression of BAX, a pro-apoptotic protein.
|
29472583 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, PEL cell lines are addicted to high levels of MCL1 expression, which are also evident in PEL tumors.
|
30111820 |
2018 |